8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Feb 6, 2026)

Filed February 6, 2026For Securities:BIIB

Summary

Biogen Inc. (BIIB) has filed a Form 8-K on February 6, 2026, to report its financial results for the fourth quarter and full year ended December 31, 2025. The core of this filing is the accompanying press release (Exhibit 99.1), which details the company's operational performance and financial condition. Investors should review this press release for specific figures regarding revenue, profitability, and other key financial metrics for the period. While the 8-K itself is a formal notification of the results announcement, the substantive details are contained within the furnished press release. This report serves as an official communication channel for the market to access Biogen's latest financial performance indicators. Investors are advised to consult Exhibit 99.1 for a comprehensive understanding of Biogen's fourth-quarter and year-end 2025 financial outcomes and their potential implications.

Key Highlights

  • 1Biogen Inc. announced its Q4 and full-year 2025 financial results on February 6, 2026.
  • 2The official results are detailed in a press release furnished as Exhibit 99.1 to the 8-K.
  • 3The filing pertains to the results of operations and financial condition for the period ending December 31, 2025.
  • 4This 8-K serves as the formal notification of the earnings announcement.
  • 5Investors must refer to the press release (Exhibit 99.1) for specific financial data and performance details.
  • 6The provided press release is furnished, not deemed filed, for purposes of certain SEC regulations.

Frequently Asked Questions

The main purpose of this Form 8-K filing is to formally announce and report Biogen Inc.'s financial results for the fourth quarter and the full year ended December 31, 2025. The detailed financial and operational information is contained within the press release furnished as Exhibit 99.1.

The specific financial numbers, including revenue, profitability, and other operational results for the fourth quarter and full year ended December 31, 2025, are located in Biogen's press release dated February 6, 2026, which is provided as Exhibit 99.1 to this 8-K filing.

This specific 8-K filing, as per Item 2.02, primarily serves to present historical results through a furnished press release. Any forward-looking statements or guidance would be detailed within that press release (Exhibit 99.1), and investors should carefully review it for such information.

When information is 'furnished' under Item 2.02, it means it is being provided to the SEC for public disclosure but is not subject to the same legal liabilities as 'filed' information under Section 18 of the Exchange Act. This is a standard practice for earnings press releases.